Clinical Trial Results:
A Phase III, Observer-Blind, Randomized, Non-influenza Vaccine Comparator-Controlled, Parallel-Group, Multi-Country Study in Children Aged 6–35 Months to Assess the Safety and Efficacy of Abbott’s Candidate Quadrivalent Influenza Vaccine
Summary
|
|
EudraCT number |
2016-004904-74 |
Trial protocol |
SK DK EE CZ LT BG IT SI ES FR HR HU RO |
Global end of trial date |
31 Jan 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Jul 2020
|
First version publication date |
09 Jul 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
INFQ3003
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Abbott Biologicals B.V.
|
||
Sponsor organisation address |
C.J. van Houtenlaan 36, Weesp, Netherlands, NL-1381 CP
|
||
Public contact |
Public Affairs Director, Abbott Products Operations AG, hind.ounis@abbott.com
|
||
Scientific contact |
Global Clinical Director, Abbott Healthcare Products B.V., serge.vandewitte@abbott.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-001782-PIP01-15 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
31 Jan 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Jan 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate, in children aged 6 to 35 months, the absolute efficacy of quadrivalent influenza vaccine (QIV) in the prevention of symptomatic influenza infection due to any circulating seasonal influenza strain compared with a non-influenza (child) vaccine (NIV), assessed by reverse transcription polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B infection.
|
||
Protection of trial subjects |
The study was conducted in compliance with Good Clinical Practice and the applicable national regulations to assure that the rights, safety, and well-being of the participating study subjects were protected, consistent with the ethical principles that have their origin in the Declaration of Helsinki.
Following the vaccination, subjects were observed for at least 30 minutes to monitor for any immediate adverse reactions (appropriate medical treatment and supervision were readily available in case of an anaphylactic event).
|
||
Background therapy |
- | ||
Evidence for comparator |
NIVs were selected as the control group for this study based on recommendations outlined in the Guideline on Influenza Vaccines by the European Medicines Agency (EMA/CHMP/VWP/457259/2014). As per the guideline, NIVs were used to avoid the use of placebo in this vulnerable population and to provide a benefit to study participation for all study subjects. The NIVs selected for the control group were vaccines that were approved for use and commonly used in routine medical practice for the respective age ranges. The selected NIV controls needed to complement the existing national/regional childhood vaccination programs and therefore the eventual usability of each of the NIVs varied by country/region. | ||
Actual start date of recruitment |
01 Sep 2017
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
8 Months | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Bulgaria: 160
|
||
Country: Number of subjects enrolled |
Czech Republic: 92
|
||
Country: Number of subjects enrolled |
Denmark: 14
|
||
Country: Number of subjects enrolled |
Estonia: 569
|
||
Country: Number of subjects enrolled |
Hungary: 59
|
||
Country: Number of subjects enrolled |
Italy: 91
|
||
Country: Number of subjects enrolled |
Lithuania: 250
|
||
Country: Number of subjects enrolled |
Malaysia: 9
|
||
Country: Number of subjects enrolled |
Philippines: 285
|
||
Country: Number of subjects enrolled |
Romania: 45
|
||
Country: Number of subjects enrolled |
Slovakia: 30
|
||
Country: Number of subjects enrolled |
Slovenia: 6
|
||
Country: Number of subjects enrolled |
Spain: 224
|
||
Country: Number of subjects enrolled |
Thailand: 152
|
||
Country: Number of subjects enrolled |
Vietnam: 21
|
||
Worldwide total number of subjects |
2007
|
||
EEA total number of subjects |
1540
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
1341
|
||
Children (2-11 years) |
666
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
The study was conducted at 56 centers across Europe and Asia and comprised at least 3 clinic visits and 3 telephone contacts (TCs) per completed subject. The study included 2 cohorts (Cohort 1 and Cohort 2) and was conducted over 3 influenza seasons (Northern Hemisphere [NH] 2017/2018, NH 2018/2019, and Southern Hemisphere [SH] 2019). | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
Eligible subjects were randomly assigned to vaccination with QIV or a NIV in a 1:1 ratio. Study comprised of a primary immunization period (including Cohort 1 Year 1 and Cohort 2) and a revaccination period (including subset of subjects from Cohort 1 who were exposed to QIV in Year 1). Results data are presented for the primary immunization period. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Overall study (overall period)
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||||||||||||||
Blinding implementation details |
Observer blind: the subject and their parents/legally acceptable representative (LAR), the Investigator, and those responsible for evaluation of any study endpoint (e.g., safety, reactogenicity, immunogenicity, and efficacy) and for review/analysis of study data were unaware of the treatment assignments. To maintain blinding, the vaccination was performed by authorized medical site study personnel who did not participate in any of the study clinical evaluations.
|
||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Quadrivalent Influenza Vaccine | ||||||||||||||||||||||||||||||
Arm description |
Each subject received 2 doses of QIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Quadrivalent Influenza Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
QIV, Influvac® Tetra
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received 2 doses of 0.5 milliliters (mL) each of QIV administered by intramuscular injection in the deltoid muscle of the upper arm or in the anterolateral thigh.
For the NH QIV (subunit, inactivated), the active drug substance was 15 micrograms (µg) of hemagglutinin (HA) of each of the 4 viral strains recommended for the NH season by the World Health Organization (WHO) and the Committee for Medicinal Products for Human Use as follows:
• Cohort 1 Year 1 (Season NH 2017/2018)
• Cohort 2 NH (Season NH 2018/2019)
For the SH QIV (subunit, inactivated) the active drug substance was 15 µg of HA of each of the 4 viral strains recommended for the SH season by the WHO as follows:
• Cohort 2 SH (Season SH 2019)
|
||||||||||||||||||||||||||||||
Arm title
|
Non-influenza Vaccine | ||||||||||||||||||||||||||||||
Arm description |
Each subject received 2 doses of a NIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. For each subject enrolled in the NIV control group, only 1 reference product was used. | ||||||||||||||||||||||||||||||
Arm type |
Control vaccine | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Non-influenza Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
NIV
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received 2 doses of 0.25 to 0.5 mL each of a NIV control administered by intramuscular injection in the deltoid muscle of the upper arm or in the anterolateral thigh.
Depending on the subject’s age and the routine childhood vaccination programs in each of the respective countries, the NIV controls used could be:
For infants 6 to 11 months of age:
• Pneumococcal conjugate vaccine or meningococcal group C conjugate vaccine.
For toddlers 12 to 35 months of age:
• Hepatitis A vaccine, tick borne encephalitis vaccine or varicella vaccine.
Dose and administration details apply for subjects randomized to a NIV in both Cohorts 1 and 2.
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Quadrivalent Influenza Vaccine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Each subject received 2 doses of QIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Non-influenza Vaccine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Each subject received 2 doses of a NIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. For each subject enrolled in the NIV control group, only 1 reference product was used. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Quadrivalent Influenza Vaccine
|
||
Reporting group description |
Each subject received 2 doses of QIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. | ||
Reporting group title |
Non-influenza Vaccine
|
||
Reporting group description |
Each subject received 2 doses of a NIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. For each subject enrolled in the NIV control group, only 1 reference product was used. |
|
||||||||||
End point title |
First occurrence of RT-PCR-confirmed influenza A and/or B illness of any severity due to any circulating seasonal influenza strain | |||||||||
End point description |
The primary endpoint assessed the first occurrence of RT-PCR-confirmed influenza A and/or B illness of any severity due to any circulating seasonal influenza strain occurring between 28 days following the second vaccine administration and the end of the primary immunization influenza surveillance period. The number of subjects with RT-PCR-confirmed influenza A and/or B infection due to any circulating strain is presented for the full analysis (FA) sample. The analysis excluded subjects who did not receive the second vaccination, those who dropped-out or withdrew before 28 days after the second vaccination, and those with first occurrence of RT-PCR-confirmed influenza between the first vaccination and 28 days after the second vaccination.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]) up to TC3 (end of the primary immunization influenza surveillance period).
|
|||||||||
|
||||||||||
Statistical analysis title |
Absolute vaccine efficacy; primary analysis | |||||||||
Statistical analysis description |
Absolute vaccine efficacy of QIV compared with NIVs in the prevention of symptomatic influenza infection due to any circulating seasonal influenza strain. Time to first occurrence was measured from Day 28 after second study vaccination. Hazard ratio (HR) was obtained from a Cox Proportional Hazards model. For purpose of the analysis, vaccine efficacy was derived as 1-HR. Model contained age group (6-11, 12-18, 19-24, 25-35 and 6-24 months), country and vaccine group (QIV or NIV) as factors.
|
|||||||||
Comparison groups |
Non-influenza Vaccine v Quadrivalent Influenza Vaccine
|
|||||||||
Number of subjects included in analysis |
1972
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
Method |
||||||||||
Parameter type |
Absolute vaccine efficacy of QIV | |||||||||
Point estimate |
0.54
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
0.37 | |||||||||
upper limit |
0.66 |
|
||||||||||
End point title |
First occurrence of RT-PCR-confirmed influenza A and/or B illness of any severity due to antigenically-matching influenza strains | |||||||||
End point description |
A secondary endpoint assessed the first occurrence of RT-PCR-confirmed influenza A and/or B illness of any severity due to antigenically-matching influenza strains occurring between 28 days following the second vaccine administration and the end of the primary immunization influenza surveillance period. The number of subjects with RT-PCR-confirmed influenza A and/or B infection due to antigenically-matching strains is presented for the FA sample. The analysis excluded subjects who did not receive the second vaccination, those who dropped-out or withdrew before 28 days after the second vaccination, and those with first occurrence of RT-PCR-confirmed influenza between the first vaccination and 28 days after the second vaccination.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]) up to TC3 (end of the primary immunization influenza surveillance period).
|
|||||||||
|
||||||||||
Statistical analysis title |
Absolute vaccine efficacy; secondary analysis | |||||||||
Statistical analysis description |
Absolute vaccine efficacy of QIV compared with NIVs in the prevention of symptomatic influenza infection due to antigenically-matching influenza strains. Time to first occurrence was measured from Day 28 after second study vaccination. The HR was obtained from a Cox Proportional Hazards model. For purpose of the analysis, vaccine efficacy was derived as 1-HR. Model contained age group (6-11, 12-18, 19-24, 25-35 and 6-24 months), country and vaccine group (QIV or NIV) as factors.
|
|||||||||
Comparison groups |
Quadrivalent Influenza Vaccine v Non-influenza Vaccine
|
|||||||||
Number of subjects included in analysis |
1972
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
Method |
||||||||||
Parameter type |
Absolute vaccine efficacy of QIV | |||||||||
Point estimate |
0.68
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
0.45 | |||||||||
upper limit |
0.81 |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Pre- and post-vaccination geometric mean hemagglutination inhibition (HI) antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage | ||||||||||||||||||||||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the geometric mean titer with respect to the HI assay. The pre-first vaccination and post-second vaccination geometric mean HI antibody titers against each of the indicated vaccine strains are presented for the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 or a NIV during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Pre-vaccination: Visit 1 (Day 1). Post-vaccination: Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Pre- and post-vaccination geometric mean virus neutralization (VN) antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage [1] | ||||||||||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the geometric mean titer with respect to the VN assay. The pre-first vaccination and post-second vaccination geometric mean VN antibody titers against each of the indicated vaccine strains are presented for the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Pre-vaccination: Visit 1 (Day 1). Post-vaccination: Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The VN and NI assays were only performed for a random subset of subjects who were vaccinated with QIV from Cohort 1. Subjects vaccinated with a NIV are therefore not applicable for reporting of this end point. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Pre- and post-vaccination geometric mean neuraminidase inhibition (NI) antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage [2] | ||||||||||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the geometric mean titer with respect to the NI assay. The pre-first vaccination and post-second vaccination geometric mean NI antibody titers against each of the indicated vaccine strains are presented for the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Pre-vaccination: Visit 1 (Day 1). Post-vaccination: Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The VN and NI assays were only performed for a random subset of subjects who were vaccinated with QIV from Cohort 1. Subjects vaccinated with a NIV are therefore not applicable for reporting of this end point. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Post-vaccination geometric mean fold increases in HI antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage | ||||||||||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the geometric mean fold increase with respect to HI titers. The post-vaccination geometric mean fold increase in HI antibody titers against each of the indicated vaccine strains are presented for the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 or a NIV during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
At Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Post-vaccination geometric mean fold increases in VN antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage [3] | ||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the geometric mean fold increase with respect to VN titers. The post-vaccination geometric mean fold increase in VN antibody titers against each of the indicated vaccine strains are presented for the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
At Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The VN and NI assays were only performed for a random subset of subjects who were vaccinated with QIV from Cohort 1. Subjects vaccinated with a NIV are therefore not applicable for reporting of this end point. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Post-vaccination geometric mean fold increases in NI antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage [4] | ||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the geometric mean fold increase with respect to NI titers. The post-vaccination geometric mean fold increase in NI antibody titers against each of the indicated vaccine strains are presented for the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
At Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The VN and NI assays were only performed for a random subset of subjects who were vaccinated with QIV from Cohort 1. Subjects vaccinated with a NIV are therefore not applicable for reporting of this end point. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Seroconversion rates based on HI antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage | ||||||||||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the seroconversion rate with respect to HI titers. Seroconversion was defined as becoming seropositive (titer ≥ 10) if seronegative (titer < 10) at enrollment, or (at least) a 4-fold rise in titer if seropositive (titer ≥ 10) at enrollment. Seroconversion rates for HI are presented as the percentage of seroconverted subjects against each of the indicated vaccine strains. Analysis was performed on the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 or a NIV during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
At Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Seroconversion rates based on VN antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage [5] | ||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the seroconversion rate with respect to VN titers. Seroconversion was defined as becoming seropositive (titer ≥ 10) if seronegative (titer < 10) at enrollment, or (at least) a 4-fold rise in titer if seropositive (titer ≥ 10) at enrollment. Seroconversion rates for VN are presented as the percentage of seroconverted subjects against each of the indicated vaccine strains. Analysis was performed on the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
At Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The VN and NI assays were only performed for a random subset of subjects who were vaccinated with QIV from Cohort 1. Subjects vaccinated with a NIV are therefore not applicable for reporting of this end point. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Seroconversion rates based on NI antibody titers against the influenza A and B strains: A(H3N2), A(H1N1), B/Victoria lineage and B/Yamagata lineage [6] | ||||||||||||||||
End point description |
Characterization of the immunogenicity of each of the strains in QIV was assessed by deriving the seroconversion rate with respect to NI titers. Seroconversion was defined as becoming seropositive (titer ≥ 10) if seronegative (titer < 10) at enrollment, or (at least) a 4-fold rise in titer if seropositive (titer ≥ 10) at enrollment. Seroconversion rates for NI are presented as the percentage of seroconverted subjects against each of the indicated vaccine strains. Analysis was performed on the immunogenicity sample for subjects in Cohort 1 (i.e., received QIV recommended for the NH season 2017/2018 during the primary immunogenicity period). n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
At Visit 3 (28-33 days after second vaccination [equivalent to 56-66 days after Day 1]).
|
||||||||||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The VN and NI assays were only performed for a random subset of subjects who were vaccinated with QIV from Cohort 1. Subjects vaccinated with a NIV are therefore not applicable for reporting of this end point. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
Percentage of subjects with solicited systemic reactions | ||||||||||||||||||||||||||||||
End point description |
A subject diary was used to record pre-specified systemic reactions occurring during the first 7 days after vaccination (solicited reactogenicity). The diary was completed by the parents/LAR, as appropriate. The following systemic reactions were assessed: fever, irritability/fussiness, drowsiness, sweating, diarrhea/vomiting and loss of appetite. The percentage of subjects with solicited systemic reactions during the primary immunization period are presented for the safety sample. n = number of subjects with non-missing data for each parameter analyzed.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
Period of 7 days after each of the 2 study vaccinations (first vaccination at Visit 1 [Day 1] and second vaccination at Visit 2 [28-33 days after Day 1]).
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Percentage of subjects with solicited local reactions | |||||||||||||||||||||||||||
End point description |
A subject diary was used to record pre-specified vaccination site (local) reactions occurring during the first 7 days after vaccination (solicited reactogenicity). The diary was completed by the parents/LAR, as appropriate. The following vaccination site reactions were assessed: erythema, swelling, induration, vaccination site pain and ecchymosis. Percentages of subjects with solicited local reactions during the primary immunization period are presented for the safety sample. n = number of subjects with non-missing data for each parameter analyzed.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
Period of 7 days after each of the 2 study vaccinations (first vaccination at Visit 1 [Day 1] and second vaccination at Visit 2 [28-33 days after Day 1]).
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Treatment-emergent adverse events are reported for the primary immunization period from Day 1 up to the final safety follow-up TC. Overall time frame of between 6 and 8 months after first vaccination.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The safety sample consisted of all subjects who were in the all subjects vaccinated sample and had at least 1 post-vaccination safety observation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
20.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Quadrivalent Influenza Vaccine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Each subject received 2 doses of QIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Non-influenza Vaccine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Each subject received 2 doses of a NIV. The first vaccination was administered on Day 1 (Visit 1), followed by a second vaccination 28 to 33 days after Day 1 (Visit 2). The final safety follow-up (TC3) was planned between 6 and 8 months after the first vaccination. For each subject enrolled in the NIV control group, only 1 reference product was used. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
11 Apr 2017 |
Protocol amendment 1 incorporated the following changes: exclusion criteria changes (2 added and 2 others revised), clarification for the selection of control vaccines for different age groups, clarification of Investigator instructions in case of immediate (serious) adverse reactions, and addition of specific guidance on the reporting of suspected unexpected serious adverse reactions. |
||
21 Feb 2018 |
Protocol amendment 2 incorporated the following changes: the planned interim analysis was removed due to lower than planned recruitment of subjects into Cohort 1, number of countries and sites was expanded to enable recruitment of up to 2,000 subjects in Cohort 2, and clarification regarding adverse events of special interest. |
||
12 Jul 2018 |
Protocol amendment 3 incorporated the following changes: enrollment of Cohort 2 was extended into an additional influenza season. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |